In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively. Read More
Source link
'I love my job': A Canadian astronaut trains (and waits) to go to space
Jenni Gibbons talks about becoming the third Canadian woman to become an astronaut, the job’s ups and downs, and why space exploration matters. Source link








